Skip to main content
Sanuj Ravindran, MD, Internal Medicine, New York, NY

Sanuj Ravindran MD MBA


Physician

Join to View Full Profile
  • 146 Chambers StSuite #5New York, NY 10007

  • Phone+1 917-546-6997

Dr. Ravindran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • I am a biotechnology executive and company builder. Having first worked as a VC for 10 years, I’ve spent the past 12 years leading emerging biotech companies across various therapeutic areas and stages of development.

Education & Training

  • University of Rochester Medical Center
    University of Rochester Medical CenterResidency, Internal Medicine, 1999 - 2000
  • Sidney Kimmel Medical College at Thomas Jefferson University/TJUH
    Sidney Kimmel Medical College at Thomas Jefferson University/TJUHInternship, Internal Medicine, 1998 - 1999
  • Sidney Kimmel Medical College at Thomas Jefferson University
    Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1998

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1999 - 2025
  • IL State Medical License
    IL State Medical License 2001 - 2011
  • PA State Medical License
    PA State Medical License 2000 - 2001

Publications & Presentations

PubMed

Press Mentions

  • Discovered in the Valley of the One-Eyed Lambs, a Toxic Weed Fuels a Cancer-Drug Gold Rush — and a Quandary
    Discovered in the Valley of the One-Eyed Lambs, a Toxic Weed Fuels a Cancer-Drug Gold Rush — and a QuandaryOctober 24th, 2019
  • A Livestock-Poison-Turned-Drug Might Save Her from Endless Cancer Surgeries. But if She Helps Test It, Could She Afford to Keep Taking It?
    A Livestock-Poison-Turned-Drug Might Save Her from Endless Cancer Surgeries. But if She Helps Test It, Could She Afford to Keep Taking It?October 23rd, 2019
  • PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
    PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin SyndromeApril 1st, 2019
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: